CoChat

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

Open access

The DOI matches its Crossref record; 793 of the 793 references it cites were found in a registry or an index; 233 of the 632 sources its claims cite were checked for support.

Abstract

The human gastrointestinal tract is populated with a diverse microbial community. The vast genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every aspect of human biology, including health maintenance, development, aging, and disease. The advent of new sequencing technologies and culture-independent methods has allowed researchers to move beyond correlative studies toward mechanistic explorations to shed light on microbiome–host interactions. Evidence has unveiled the bidirectional communication between the gut microbiome and the central nervous system, referred to as the “microbiota–gut–brain axis”. The microbiota–gut–brain axis represents an important regulator of glial functions, making it an actionable target to ameliorate the development and progression of neurodegenerative diseases. In this review, we discuss the mechanisms of the microbiota–gut–brain axis in neurodegenerative diseases. As the gut microbiome provides essential cues to microglia, astrocytes, and oligodendrocytes, we examine the communications between gut microbiota and these glial cells during healthy states and neurodegenerative diseases. Subsequently, we discuss the mechanisms of the microbiota–gut–brain axis in neurodegenerative diseases using a metabolite-centric approach, while also examining the role of gut microbiota-related neurotransmitters and gut hormones. Next, we examine the potential of targeting the intestinal barrier, blood–brain barrier, meninges, and peripheral immune system to counteract glial dysfunction in neurodegeneration. Finally, we conclude by assessing the pre-clinical and clinical evidence of probiotics, prebiotics, and fecal microbiota transplantation in neurodegenerative diseases. A thorough comprehension of the microbiota–gut–brain axis will foster the development of effective therapeutic interventions for the management of neurodegenerative diseases.

Overview

CoChat Summary

TL;DR

This review synthesizes mechanistic and therapeutic evidence on the microbiota–gut–brain axis in neurodegenerative diseases, emphasizing bidirectional communication between gut microbiota and glial cells (microglia, astrocytes, oligodendrocytes). It argues that gut-derived metabolites, neurotransmitters, and hormones modulate glial function via the intestinal barrier, blood–brain barrier, meninges, and peripheral immune system, and assesses probiotics, prebiotics, and FMT as therapeutic strategies.

Key findings

  • The gut microbiome regulates microglial maturation and function largely via short-chain fatty acids (SCFAs); germ-free and antibiotic-treated mice show impaired microglial immune responses that are partially restored by recolonization or SCFA supplementation. Among neuronal and glial cells, microglia are described as the most vulnerable to gut microbiome alterations.
  • In AD models, germ-free or antibiotic-treated APP/PS1 and 5xFAD mice show reduced Aβ pathology and microglial activation, and FMT from AD patients or conventionally raised mice restores pathology; effects are sex-dependent (e.g., absent in female APP/PS1-21 mice). In PD, germ-free/antibiotic-treated α-synuclein-overexpressing mice show less pathology, and FMT from PD patients restores motor dysfunction.
  • Metabolite-centric evidence is context-dependent: SCFAs are largely neuroprotective in PD but show conflicting (both protective and detrimental) effects in AD; TMAO promotes microglial/astrocytic activation and Aβ/tau pathology; secondary bile acids UDCA/TUDCA are neuroprotective; indole derivatives act via AHR; BCAAs promote anti-inflammatory microglial phenotypes; nicotinamide (NAM) is reduced in ALS serum and CSF.
  • Clinical translation is mixed: probiotics/prebiotics improve constipation-related parameters and some cognitive/motor scores in PD and MCI trials, but several AD trials show no significant cognitive benefit; the paper notes a 95% positive-result rate in human microbiota-associated rodent studies warrants caution.

Methods

  • Narrative review (not a primary study) covering mechanisms of the microbiota–gut–brain axis in AD, PD, ALS, HD, and FTD, with emphasis on glial interactions.
  • Synthesizes preclinical (germ-free, antibiotic-treated, FMT, transgenic mouse models) and clinical evidence, including tables of in vivo probiotic/prebiotic/FMT studies and completed/ongoing clinical trials (Tables 1–5).
  • Uses a metabolite-centric framing (SCFAs, bile acids, TMAO, tryptophan/indoles, PUFAs, BCAAs, NAM) plus gut microbiota-related neurotransmitters (serotonin, GABA, dopamine, acetylcholine, glutamate) and gut hormones (ghrelin, leptin, GLP-1).

Limitations

  • Stated: establishing causality between altered gut microbiome and disease is difficult (causative vs. consequential vs. bystander); animal models do not fully recapitulate human microbiome/pathobiology; the 95% positive-result rate in human microbiota-associated rodents demands caution against overstating causal claims.
  • Stated: many SCFA studies reporting detrimental effects used germ-free mice, which are physiologically abnormal, limiting extrapolation to humans; heterogeneity across AD mouse models complicates predicting SCFA implications.
  • Stated: clinical trials often lack gut microbiome profiling, limiting pre/post comparison; few trials exist in ALS, FTD, and HD; FMT is limited by variable engraftment, limited scalability, lack of standardized protocols, and pathogen-transmission risk. Evident from the text: much of the mechanistic evidence is preclinical, and several findings (e.g., TMAO in PD, astrocyte studies relying on GFAP densitometry) are explicitly described as conflicting or methodologically limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01743-1

Cites

793 of 793 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The microbiota–gut–brain axis. The bidirectional communication between the gut microbiome and the brain is mediated by the immune system, vagus nerve, enteric nervous system, neuroendocrine system, and circulatory system. Alterations in gut microbiota have been linked to the development of autism spectrum disorders, anxiety, depressive-like behavior, impaired physical performance, and motivation, as well as neurodegenerative diseases. This figure was created with BioRender (https://biorender.com/)
Fig. 1 The microbiota–gut–brain axis. The bidirectional communication between the gut microbiome and the brain is mediated by the immune system, vagus nerve, enteric nervous system, neuroendocrine system, and circulatory system. Alterations in gut microbiota have been linked to the development of autism spectrum disorders, anxiety, depressive-like behavior, impaired physical performance, and motivation, as well as neurodegenerative diseases. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 2 Microglial activation and neurodegeneration. Aging induces microglial activation by activating the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling pathway. Misfolded proteins and protein aggregates induce microglial activation by impairing microglial autophagy. Stage-1 DAM represents a transitory and functional subtype with a higher capacity of phagocytosis initiated by a TREM2-independent mechanism, whereas stage-2 DAM represents a dysfunctional state initiated by a TREM2-dependent mechanism. The microglial spleen tyrosine kinase (SYK) signaling provides metabolic support to facilitate microglial transition into stage-2 DAM. Maladaptive microglial-T-cell signaling drives neurodegeneration by releasing neurotoxic factors. Microglial activation creates a feed-forward vicious cycle that aggravates neurodegeneration as activated microglia contribute to the propagation of protein aggregates into unaffected brain regions. This figure was created with BioRender (https://biorender.com/)
Fig. 2 Microglial activation and neurodegeneration. Aging induces microglial activation by activating the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling pathway. Misfolded proteins and protein aggregates induce microglial activation by impairing microglial autophagy. Stage-1 DAM represents a transitory and functional subtype with a higher capacity of phagocytosis initiated by a TREM2-independent mechanism, whereas stage-2 DAM represents a dysfunctional state initiated by a TREM2-dependent mechanism. The microglial spleen tyrosine kinase (SYK) signaling provides metabolic support to facilitate microglial transition into stage-2 DAM. Maladaptive microglial-T-cell signaling drives neurodegeneration by releasing neurotoxic factors. Microglial activation creates a feed-forward vicious cycle that aggravates neurodegeneration as activated microglia contribute to the propagation of protein aggregates into unaffected brain regions. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 3 Microbiota–gut–brain axis in Alzheimer’s disease. a Short-chain fatty acids (SCFAs) exert their neuroprotective effects by acting as endogenous ligands for G-protein-coupled receptors (GPCRs) and modulating gene expression by inhibiting histone deacetylases (HDACs). b Trimethylamine N-oxide (TMAO) promotes microglial activation, neuroinflammation, Aβ and tau pathology. c Neuroprotective bile acids (BAs), including UDCA and TUDCA, inhibit neuroinflammation via direct and indirect pathways. In the direct pathway, UDCA and TUDCA activate the nuclear receptor Farnesoid X receptor (FXR) and membrane receptor Takeda G-protein-coupled receptor 5 (TGR5) found in microglia and neurons. In the indirect pathway, UDCA and TUDCA provide signals to the central nervous system indirectly via intestinal TGR5-dependent glucagon-like peptide-1 (GLP-1) pathway and intestinal FXR-dependent fibroblast growth factor 15 or 19 (FGF15/19) pathway. d Tryptophan and indole derivatives activate microglial aryl hydrocarbon receptor (AHR) signaling to inhibit microglial activation and neuroinflammation. e Polyunsaturated fatty acids (PUFAs): omega-3 fatty acids exhibit neuroprotective effects in Alzheimer’s disease, whereas omega-6 fatty acid arachidonic acid and its pro-inflammatory metabolites induce microglial activation. This figure was created with BioRender (https://biorender.com/)
Fig. 3 Microbiota–gut–brain axis in Alzheimer’s disease. a Short-chain fatty acids (SCFAs) exert their neuroprotective effects by acting as endogenous ligands for G-protein-coupled receptors (GPCRs) and modulating gene expression by inhibiting histone deacetylases (HDACs). b Trimethylamine N-oxide (TMAO) promotes microglial activation, neuroinflammation, Aβ and tau pathology. c Neuroprotective bile acids (BAs), including UDCA and TUDCA, inhibit neuroinflammation via direct and indirect pathways. In the direct pathway, UDCA and TUDCA activate the nuclear receptor Farnesoid X receptor (FXR) and membrane receptor Takeda G-protein-coupled receptor 5 (TGR5) found in microglia and neurons. In the indirect pathway, UDCA and TUDCA provide signals to the central nervous system indirectly via intestinal TGR5-dependent glucagon-like peptide-1 (GLP-1) pathway and intestinal FXR-dependent fibroblast growth factor 15 or 19 (FGF15/19) pathway. d Tryptophan and indole derivatives activate microglial aryl hydrocarbon receptor (AHR) signaling to inhibit microglial activation and neuroinflammation. e Polyunsaturated fatty acids (PUFAs): omega-3 fatty acids exhibit neuroprotective effects in Alzheimer’s disease, whereas omega-6 fatty acid arachidonic acid and its pro-inflammatory metabolites induce microglial activation. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 4 Microbiota–gut–brain axis in Parkinson’s disease. a Short-chain fatty acids (SCFAs) exert their neuroprotective effects by acting as endogenous ligands for G-protein-coupled receptors (GPCRs) and modulating gene expression by inhibiting histone deacetylases (HDACs). b Neuroprotective bile acids (BAs), including UDCA and TUDCA, inhibit neuroinflammation via direct and indirect pathways. In the direct pathway, UDCA and TUDCA activate the nuclear receptor Farnesoid X receptor (FXR) and membrane receptor Takeda G-protein-coupled receptor 5 (TGR5) found in microglia and neurons. In the indirect pathway, UDCA and TUDCA provide signals to the central nervous system indirectly via intestinal TGR5-dependent glucagon-like peptide-1 (GLP-1) pathway and intestinal FXR-dependent fibroblast growth factor 15 or 19 (FGF15/19) pathway. c Trimethylamine N-oxide (TMAO) promotes microglial activation and neuroinflammation. However, contradictory findings have been reported regarding the roles of TMAO in PD. d Tryptophan and indole derivatives activate microglial aryl hydrocarbon receptor (AHR) signaling to inhibit microglial activation and neuroinflammation. e Branched-chain amino acids (BCAAs) promote anti-inflammatory microglial phenotypes. This figure was created with BioRender (https://biorender.com/)
Fig. 4 Microbiota–gut–brain axis in Parkinson’s disease. a Short-chain fatty acids (SCFAs) exert their neuroprotective effects by acting as endogenous ligands for G-protein-coupled receptors (GPCRs) and modulating gene expression by inhibiting histone deacetylases (HDACs). b Neuroprotective bile acids (BAs), including UDCA and TUDCA, inhibit neuroinflammation via direct and indirect pathways. In the direct pathway, UDCA and TUDCA activate the nuclear receptor Farnesoid X receptor (FXR) and membrane receptor Takeda G-protein-coupled receptor 5 (TGR5) found in microglia and neurons. In the indirect pathway, UDCA and TUDCA provide signals to the central nervous system indirectly via intestinal TGR5-dependent glucagon-like peptide-1 (GLP-1) pathway and intestinal FXR-dependent fibroblast growth factor 15 or 19 (FGF15/19) pathway. c Trimethylamine N-oxide (TMAO) promotes microglial activation and neuroinflammation. However, contradictory findings have been reported regarding the roles of TMAO in PD. d Tryptophan and indole derivatives activate microglial aryl hydrocarbon receptor (AHR) signaling to inhibit microglial activation and neuroinflammation. e Branched-chain amino acids (BCAAs) promote anti-inflammatory microglial phenotypes. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 5 Improving microbiota–gut–brain axis via the intestinal barrier. a High-fiber diets contribute to a healthy gut microbiome and enhance intestinal barrier integrity by increasing SCFAs-producing species, and fiber-degrading species and promoting resistance to perturbations. Indole and its derivatives improve intestinal barrier integrity by activating epithelial aryl hydrocarbon receptors (AHR). b Low-fiber diets, aging and sleep deprivation contribute to dysbiosis and disrupt intestinal barrier integrity by reducing SCFAs-producing species and fiber-degrading species while increasing mucin-degrading species. Low-fiber diets induce mucosal and systemic immune depression by impairing the metabolic fitness of CD4+ T cells. This figure was created with BioRender (https://biorender.com/)
Fig. 5 Improving microbiota–gut–brain axis via the intestinal barrier. a High-fiber diets contribute to a healthy gut microbiome and enhance intestinal barrier integrity by increasing SCFAs-producing species, and fiber-degrading species and promoting resistance to perturbations. Indole and its derivatives improve intestinal barrier integrity by activating epithelial aryl hydrocarbon receptors (AHR). b Low-fiber diets, aging and sleep deprivation contribute to dysbiosis and disrupt intestinal barrier integrity by reducing SCFAs-producing species and fiber-degrading species while increasing mucin-degrading species. Low-fiber diets induce mucosal and systemic immune depression by impairing the metabolic fitness of CD4+ T cells. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 6 Improving microbiota–gut–brain axis via the blood–brain barrier. a SCFAs and p-cresol glucuronide improve BBB integrity and prevent glial activation. b Elevated levels of trimethylamine-N-oxide (TMAO) has been reported in the plasma and cerebrospinal fluid of individuals with mild cognitive impairment, Alzheimer’s disease (AD) and Parkinson’s disease (PD). TMAO is detrimental to BBB integrity and induces glial activation. This figure was created with BioRender (https://biorender.com/)
Fig. 6 Improving microbiota–gut–brain axis via the blood–brain barrier. a SCFAs and p-cresol glucuronide improve BBB integrity and prevent glial activation. b Elevated levels of trimethylamine-N-oxide (TMAO) has been reported in the plasma and cerebrospinal fluid of individuals with mild cognitive impairment, Alzheimer’s disease (AD) and Parkinson’s disease (PD). TMAO is detrimental to BBB integrity and induces glial activation. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central

Verification

Claims the paper makes

111 Valid · 10 Not valid · 252 Not checked · 37 Own results and interpretations

254 more claims · 79 with their cited sources checked

Create a free account to see all 410 claims and to verify the 399 references still open.

See all claims — free account
  • It may state two separate claims as one. 140
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

1 retracted

Show all 793 references

Cited by

See all 1,193

Metadata

Authors
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y.
Affiliations
  • Monash University Malaysia (MY)
  • Taylor's University (MY)
  • UCL School of Pharmacy (GB)
Corresponding author
  • How, Chee Wun
  • Khaw, Kooi Yeong
Venue
Signal Transduction and Targeted Therapy
Published
2024-02-16
Volume
9
Issue
1
Pages
37-37
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4392783067
Cited by
1,193
References
790
Citations by year
2026: 551 · 2025: 509 · 2024: 131
FWCI
48.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Greater South Information System
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
microbiota-gut-brain axis, gut microbiota, neurodegenerative diseases, glial cells, microglia, astrocytes, oligodendrocytes, gut microbiota metabolites, neurotransmitters, gastrointestinal hormones, intestinal barrier, blood-brain barrier, meninges, peripheral immune system, probiotics, prebiotics, fecal microbiota transplantation
MeSH terms
Brain-Gut Axis, Brain, Humans, Neurodegenerative Diseases, Probiotics, Prebiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. https://app.cochat.ai/papers/10.1038/s41392-024-01743-1
The paper
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024). Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01743-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.